http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-108137653-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P7-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-001 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K9-00 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K9-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P7-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P9-10 |
| filingDate | 2015-08-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2021-07-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2021-07-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-108137653-B |
| titleOfInvention | Multi-target compound with anticoagulant and antiplatelet activity, preparation method and use |
| abstract | Provided is an anticoagulation and antagonizing platelet GPIIb/IIIa receptor multi-target compound, the general formula of which is as follows: A‑L‑B‑L'‑C, wherein A and B are binding sites with thrombin, and C is At the binding site of platelet GPIIb/IIIa receptor, L is the first linking group, and L' is the second linking group. Also provided are the preparation methods and uses of the above compounds. The compound has human thrombin inhibitory activity in vitro, platelet GPIIb/IIIa receptor inhibitory activity in vitro, and antiplatelet aggregation, in vivo anticoagulation and antithrombotic effects in vitro/in vivo. |
| priorityDate | 2015-08-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 158.